Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat

Revance Reports Fourth Quarter and Full Year 2020 Financial Results

February 22, 2021 4:05 PM EST

Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectively First full quarter of RHA® Collection of dermal fillers revenue of $10.0 million Exited 2020 with over $200 million in annualized HintMD processing volume Cash, cash equivalents and short-term investments balance of $436.5 million at year-end, with cash into 2024 Today announced positive data from JUNIPER Phase 2 Trial of DaxibotulinumtoxinA for Injection for adult upper limb spasticity Conference call and webcast today at 4:30 p.m. ET

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More